ACHN has been the subject of several other reports. BidaskClub raised Achillion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, October 5th. Zacks Investment Research downgraded Achillion Pharmaceuticals from a “hold” rating to a “sell” rating and set a $4.75 price objective for the company. in a research note on Tuesday, August 27th. Four analysts have rated the stock with a sell rating and one has given a buy rating to the company. The company presently has an average rating of “Sell” and an average price target of $3.63.
Shares of NASDAQ ACHN opened at $3.63 on Thursday. Achillion Pharmaceuticals has a 12 month low of $1.29 and a 12 month high of $5.03. The company has a market cap of $507.09 million, a price-to-earnings ratio of -7.12 and a beta of 1.57. The business has a fifty day simple moving average of $4.00 and a 200-day simple moving average of $3.40.
Institutional investors have recently made changes to their positions in the stock. Bank of Montreal Can purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $30,000. Paloma Partners Management Co purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $74,000. Jane Street Group LLC purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $78,000. SG Americas Securities LLC purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $97,000. Finally, Marshall Wace LLP purchased a new stake in Achillion Pharmaceuticals in the 2nd quarter worth about $100,000. 78.57% of the stock is owned by hedge funds and other institutional investors.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Read More: Conference Calls and Individual Investors
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.